Key Takeaways
- Utilization hit masked underlying demand: A voluntary shutdown, China supply delays and greenfield ramp-ups created an estimated ₹8–₹8.5 crores EBITDA drag, but January trends and 7% standalone volume growth suggest the trough is passing.
- Greenfield projects are the FY27 story: Sayakha (antidiabetic intermediates) and the salicylic acid plant together underpin a 12%–15% volume growth target for FY27, with backward integration set to lift gross margins by at least a couple of percentage points.
- Salicylic acid is a bet, not yet a contributor: The plant scaled above 300 tons/month but faces Chinese dumping and specification challenges; management is betting on antidumping duty eligibility from April and downstream salicylate products to eventually replicate past turnarounds in metro and ciprofloxacin.
- Formulations and oncology are the medium-term margin lever: The oncology site is pre-revenue with first commercialization in Q4; management expects formulations to lift gross contribution from the second or third year, with oncology potentially generating 40% of formulation revenue over three years.
- What to watch next quarter: Whether Sayakha hits the promised 50% utilization by March–April, the salicylic acid plant’s trajectory toward 800–1,000 tons next year, and any progress on the antidumping duty filing.
Volume & Demand Recovery
- Standalone volume up, price down: 7% YoY volume growth was offset by roughly 5% negative rate variance, reflecting the pricing pressure that management now believes has bottomed out.
- January signals inflection: Management cited encouraging month sales in January and stabilizing realizations as evidence the business has reached an inflection point after several quarters of pressure.
- FY27 volume growth anchored on new projects: Existing products are expected to deliver single-digit volume growth; the 12%–15% overall target depends on salicylic acid and Sayakha methyl amine derivatives scaling as planned.
- Export mix matters for margins: Export markets yield better selling prices, so the slightly lower export content in the December quarter depressed gross margins; penetrating European markets with existing products is a stated margin-recovery strategy.
Patil: "the same thing had happened for metro and ciprofloxacin also in past. We had got antidumping duties for 4, 5 years. And by the next round when it came, we were so profitable that we did not qualify for antidumping duty. So we feel this will turn around."
Greenfield Projects & Backward Integration
- Sayakha ramp-up on track: The facility, operational since September 2025, reached nearly 30% utilization in its first quarter and targets 50% by March–April 2026, 75% the following quarter, and 80%–90% within 12 months.
- Captive use still minimal: Sayakha currently meets only 10%–15% of captive requirements for antidiabetic intermediates; backward integration is expected to rise from roughly 12% today to 90%–100% in two to three quarters.
- Gross margin boost quantified: Full backward integration is expected to add at least a couple of percentage points to gross contribution at the company level; per an analyst’s math, the full-scale EBITDA potential of these projects is slightly upwards of ₹50 crores.
- Salicylic acid plant improving slowly: Utilization was still lower than expected in the December quarter despite scaling above 300 tons/month; operational stability in quality parameters and solid waste management has improved, and further changes are planned through the June quarter.
- Downstream salicylate block coming: Technology for downstream products is already developed and piloted; a dedicated salicylate block is expected in a quarter or two, opening access to the flavor, fragrance and cosmetics industries.
Patil: "So right now the situation is such that we are compelled to do. We have already developed technology for that. We have done piloting also for the downstream products. So we are coming up with salicylate block as well very recently in a quarter or two."
Margin Walk & Profitability Bridge
- Shutdown and ramp-up drag quantified: The voluntary shutdown for refurbishment and sub-optimal greenfield utilization together created an EBITDA drag of roughly ₹8–₹8.5 crores and a PBT drag of ₹14–₹15 crores; management could not isolate the utilization-only component.
- Inventory liquidation added pressure: Around ₹30 crores of sales came from existing stock rather than fresh production, and the inventory valuation mix (80% raw material, 20% overhead) created a roughly ₹6 crores gross margin drag.
- Capacity utilization dipped further: Utilization fell 4%–5% even from H1 FY26 levels, but management expects no such disruptions in coming quarters as the shutdown and supply-chain delays are behind the business.
- EBITDA margin trajectory: From the current 9.3%, the first target is 12%–13%; steady-state margins when all projects run smoothly should be in the 14%–15% range.
- Standalone API gross margin target: 36% is a fair assumption for FY27, supported by regulated-market sales, pickup from the US FDA-approved E22 plant, backward integration, and salicylic acid improvement.
Salicylic Acid: The Contrarian Bet
- Entry triggered a price war: When Aarti entered, China crashed prices as an entry barrier, the same pattern seen earlier with metformin and ciprofloxacin; management expects the cycle to turn once antidumping duties are secured.
- Antidumping duty timeline: Aarti becomes eligible to apply from April 2026; filing is expected by the first quarter or end of Q1, with the process taking 6–9 months after application.
- Pricing slightly improved: Chinese dumping continues, but dollar rate movements have lifted realizations modestly versus last quarter.
- Technology upgrade under evaluation: Drastic specification changes since the plant’s April 2024 commissioning forced process tweaks; new technology for the physical chemistry of salicylic acid is being explored for adoption.
- Plant target for next year: Management is targeting 800–1,000 metric tons, acknowledging the ramp-up is going slightly slowly.
Formulations & Oncology: The Medium-Term Margin Story
- Oncology site is pre-revenue but ready: A dedicated US FDA-approved manufacturing site exists; the first product will be commercialized in Q4.
- Revenue ambition: Management estimates about 40% of formulation revenue over the next three years can come from oncology, with 40%–50% of formulation investment directed there.
- Asset turn and capacity: The oncology business involves roughly ₹200 crores spread over time including capex and product development; expected asset turn is 1.5x–1.75x at peak, with capacity of roughly 30 crore pills.
- B2B partners secured pre-filing: In most territories, dossier partners are locked in before regulatory filing, de-risking the commercial pathway.
- Formulations margin impact is back-end loaded: The positive gross contribution impact is expected from the second and third year, not immediately in FY27; oncology will add as it begins flowing into sales.
- EU GMP for Baddi: Both the oncology facility and the general oral solid side received EU GMP approval in a joint inspection, clearing a regulatory gate for European formulation sales.
Capex, Capacity & Other Initiatives
- Capex run-rate: ₹150–₹200 crores per year for the next two years, covering formulation, oncology expansion, dossier development, maintenance, brownfield expansion, a solar power plant and energy-related improvements.
- Metformin expansion: Capacity is scaling from 1,450–1,500 tons/month to 1,800–1,900 tons/month in the existing facility, with a long-term target of 2,500–3,000 tons/month; a US DMF has been prepared and filing is in process, with an audit trigger planned for the coming year.
- Cogen boiler onstream: A 25-ton cogeneration boiler is being commissioned this quarter, generating power alongside steam.
- Cardiovascular and antifungal capacity: Brownfield expansion is underway for cardiovascular products from existing lines and for antifungals due to increased demand.
- CDMO and spec chem: The business is doing contract manufacturing for a few MNCs in chlorosulfonation chemistry, where Aarti is already backward integrated; the segment is still too small to disclose separately.
- New molecule identification ongoing: The process for identifying new API and spec chem molecules is underway, with announcements expected once finalized.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Sayakha utilization ramp | 50% utilization | March–April 2026 |
| Sayakha utilization ramp | 75% utilization | Quarter following March 2026 |
| Sayakha utilization ramp | 80%–90% utilization | Within 12 months |
| Backward integration for antidiabetic | 90%–100% captive self-reliance (from ~12% today) | Two to three quarters |
| Salicylic acid plant output | 800–1,000 metric tons | Next year (FY27) |
| Antidumping duty application | File application against Chinese salicylic acid imports | Q1 FY27 or end-Q1 (eligible from April 2026) |
| Oncology first commercialization | First product launched | Q4 FY26 |
| Metformin US FDA audit | File DMF, trigger audit | Coming year |
| Standalone API gross margin | 36% | FY27 |
| EBITDA margin | 12%–13% (first target), then 14%–15% steady state | Not dated; conditional on projects running smoothly |
| FY27 volume growth | 12%–15% | FY27 |
| Capex | ₹150–₹200 crores per year | Next two years |
| Salicylate downstream block | Commission dedicated block | A quarter or two |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Consolidated revenue | ₹602.9 cr, up 8% YoY from ₹557.1 cr |
| Consolidated EBITDA | ₹56.3 cr, down 10% YoY from ₹62.3 cr |
| Consolidated EBITDA margin | 9.3%, vs 12.9% in Q2 FY26 |
| Consolidated PAT | ₹40.5 cr, up 58% YoY from ₹25.7 cr |
| Consolidated PAT margin | 6.7% |
| Standalone revenue | ₹530.0 cr, 88% of consolidated revenue |
| Standalone volume growth | 7% YoY, with negative rate variance of around 5% |
| Formulation segment revenue | ₹76.6 cr, up 58% YoY |
| Exports share in standalone revenue | 37% |
| Exports share in formulation revenue | 67% |
| Consolidated gross margin | 35.9%, impacted by ~1% from inventory sell-down |
| Sayakha facility utilization | ~30% in first quarter of operations |
| Salicylic acid production | Above 300 tons per month at Tarapur facility |
| Total consolidated debt | ~₹540 cr; standalone debt ~₹392 cr |
| EBITDA drag from Sayakha and salicylic acid plants | ~₹8.5 cr combined at EBITDA level |
| Capex guidance | ₹150 cr to ₹200 cr per year for next 2 years |